je.st
news
Home
› Daiichi Sankyo Submits Supplemental New Drug Application In Japan For LIXIANA (Edoxaban Tosilate Hydrate) For New Indications
Daiichi Sankyo Submits Supplemental New Drug Application In Japan For LIXIANA (Edoxaban Tosilate Hydrate) For New Indications
2013-12-30 06:22:57| drugdiscoveryonline News Articles
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (NDA) for its oral, once-daily direct factor Xa-inhibitor LIXIANA® (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry of Health, Labour and Welfare
Tags: new
japan
application
drug
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||